Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Genetic Testing | 59 | 2024 | 1004 | 5.830 |
Why?
|
Germ-Line Mutation | 32 | 2025 | 333 | 4.670 |
Why?
|
Genetic Predisposition to Disease | 63 | 2025 | 3137 | 4.590 |
Why?
|
Neoplasms | 44 | 2024 | 2801 | 4.280 |
Why?
|
Genome, Human | 27 | 2025 | 1273 | 3.220 |
Why?
|
Genetic Variation | 31 | 2024 | 1492 | 3.140 |
Why?
|
Genomics | 42 | 2024 | 1490 | 3.120 |
Why?
|
Neoplastic Syndromes, Hereditary | 12 | 2024 | 72 | 2.580 |
Why?
|
Databases, Genetic | 17 | 2024 | 473 | 2.310 |
Why?
|
Exome | 26 | 2024 | 1042 | 2.070 |
Why?
|
Genetic Counseling | 10 | 2024 | 221 | 1.940 |
Why?
|
Mutation | 50 | 2023 | 5808 | 1.940 |
Why?
|
Genetic Diseases, Inborn | 11 | 2024 | 446 | 1.520 |
Why?
|
Sequence Analysis, DNA | 20 | 2022 | 1762 | 1.510 |
Why?
|
Early Detection of Cancer | 9 | 2024 | 359 | 1.380 |
Why?
|
Genes, BRCA1 | 9 | 2018 | 51 | 1.360 |
Why?
|
Humans | 220 | 2025 | 124394 | 1.280 |
Why?
|
Heterozygote | 9 | 2016 | 676 | 1.280 |
Why?
|
Transcription Factors | 14 | 2025 | 2607 | 1.270 |
Why?
|
Genetics, Medical | 10 | 2020 | 117 | 1.240 |
Why?
|
Li-Fraumeni Syndrome | 4 | 2022 | 44 | 1.240 |
Why?
|
Rothmund-Thomson Syndrome | 9 | 2019 | 48 | 1.200 |
Why?
|
Child | 88 | 2025 | 24526 | 1.180 |
Why?
|
High-Throughput Nucleotide Sequencing | 14 | 2023 | 870 | 1.170 |
Why?
|
Adenomatous Polyposis Coli | 7 | 2024 | 42 | 1.090 |
Why?
|
Incidental Findings | 10 | 2023 | 124 | 1.080 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 4 | 2024 | 61 | 1.070 |
Why?
|
Gastrointestinal Neoplasms | 3 | 2024 | 79 | 1.060 |
Why?
|
Breast Neoplasms | 15 | 2018 | 2508 | 1.010 |
Why?
|
Leukemia | 4 | 2023 | 376 | 1.000 |
Why?
|
Translocation, Genetic | 4 | 2015 | 356 | 0.970 |
Why?
|
Kidney Neoplasms | 6 | 2025 | 430 | 0.910 |
Why?
|
Adenosine Triphosphatases | 7 | 2017 | 208 | 0.900 |
Why?
|
Ovarian Neoplasms | 9 | 2022 | 408 | 0.870 |
Why?
|
Saccharomyces cerevisiae | 7 | 2010 | 426 | 0.870 |
Why?
|
Computational Biology | 9 | 2018 | 820 | 0.840 |
Why?
|
Germ Cells | 10 | 2024 | 195 | 0.830 |
Why?
|
Genetic Association Studies | 8 | 2020 | 775 | 0.830 |
Why?
|
Brain Neoplasms | 10 | 2023 | 1244 | 0.820 |
Why?
|
Data Curation | 2 | 2019 | 12 | 0.800 |
Why?
|
Information Dissemination | 5 | 2019 | 186 | 0.790 |
Why?
|
DNA-Binding Proteins | 14 | 2023 | 2055 | 0.790 |
Why?
|
Repressor Proteins | 8 | 2019 | 820 | 0.760 |
Why?
|
Cell Cycle Proteins | 9 | 2016 | 645 | 0.760 |
Why?
|
Neoplasm Proteins | 4 | 2019 | 669 | 0.760 |
Why?
|
Genes, BRCA2 | 5 | 2018 | 42 | 0.740 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2017 | 810 | 0.730 |
Why?
|
Disclosure | 6 | 2019 | 154 | 0.720 |
Why?
|
Guidelines as Topic | 4 | 2017 | 198 | 0.700 |
Why?
|
Rare Diseases | 2 | 2021 | 191 | 0.690 |
Why?
|
Pharmacogenetics | 2 | 2023 | 184 | 0.690 |
Why?
|
Disease | 2 | 2018 | 129 | 0.690 |
Why?
|
RecQ Helicases | 8 | 2010 | 60 | 0.660 |
Why?
|
DNA Helicases | 5 | 2023 | 226 | 0.660 |
Why?
|
Algorithms | 8 | 2024 | 1612 | 0.650 |
Why?
|
Oncologists | 4 | 2023 | 29 | 0.650 |
Why?
|
Female | 88 | 2025 | 66301 | 0.630 |
Why?
|
Child, Preschool | 40 | 2025 | 14085 | 0.630 |
Why?
|
Tumor Suppressor Protein p53 | 8 | 2024 | 719 | 0.630 |
Why?
|
Laboratories | 2 | 2016 | 82 | 0.620 |
Why?
|
Leukemia, Myeloid, Acute | 4 | 2020 | 538 | 0.620 |
Why?
|
Male | 80 | 2025 | 61025 | 0.610 |
Why?
|
Colorectal Neoplasms | 6 | 2022 | 566 | 0.600 |
Why?
|
Chromosomal Proteins, Non-Histone | 2 | 2019 | 213 | 0.600 |
Why?
|
PTEN Phosphohydrolase | 4 | 2024 | 260 | 0.600 |
Why?
|
Molecular Sequence Annotation | 1 | 2018 | 149 | 0.590 |
Why?
|
Adult | 49 | 2025 | 29396 | 0.590 |
Why?
|
Rhabdomyosarcoma | 4 | 2024 | 201 | 0.590 |
Why?
|
Genetics, Population | 1 | 2018 | 187 | 0.580 |
Why?
|
Intellectual Disability | 2 | 2023 | 1061 | 0.580 |
Why?
|
Jews | 5 | 2003 | 32 | 0.580 |
Why?
|
Infant | 35 | 2025 | 12479 | 0.570 |
Why?
|
Research Subjects | 2 | 2015 | 55 | 0.550 |
Why?
|
Wilms Tumor | 3 | 2025 | 113 | 0.550 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 2017 | 17 | 0.550 |
Why?
|
Adolescent | 41 | 2025 | 19358 | 0.550 |
Why?
|
BRCA1 Protein | 4 | 2024 | 68 | 0.550 |
Why?
|
Parents | 5 | 2024 | 1039 | 0.540 |
Why?
|
Phenotype | 17 | 2024 | 4255 | 0.540 |
Why?
|
5'-Nucleotidase | 1 | 2016 | 16 | 0.530 |
Why?
|
Genetic Research | 3 | 2018 | 56 | 0.520 |
Why?
|
Ethics, Medical | 3 | 2018 | 395 | 0.520 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2019 | 1899 | 0.510 |
Why?
|
Chromosome Deletion | 3 | 2010 | 647 | 0.500 |
Why?
|
Nuclear Proteins | 7 | 2023 | 1272 | 0.490 |
Why?
|
Base Sequence | 16 | 2018 | 3093 | 0.490 |
Why?
|
Peutz-Jeghers Syndrome | 3 | 2024 | 27 | 0.480 |
Why?
|
Polymorphism, Single Nucleotide | 11 | 2020 | 2615 | 0.460 |
Why?
|
Ubiquitin-Protein Ligase Complexes | 3 | 2001 | 28 | 0.460 |
Why?
|
Neurofibromatosis 1 | 4 | 2017 | 61 | 0.460 |
Why?
|
Ligases | 3 | 2001 | 46 | 0.460 |
Why?
|
DNA Copy Number Variations | 7 | 2022 | 943 | 0.460 |
Why?
|
Genes, Neoplasm | 3 | 2010 | 80 | 0.460 |
Why?
|
Death | 1 | 2015 | 70 | 0.450 |
Why?
|
Alleles | 12 | 2020 | 1614 | 0.450 |
Why?
|
Antineoplastic Agents | 8 | 2021 | 1674 | 0.450 |
Why?
|
Liver Neoplasms | 7 | 2025 | 1319 | 0.450 |
Why?
|
Decision Making | 8 | 2024 | 656 | 0.440 |
Why?
|
Neurodevelopmental Disorders | 1 | 2019 | 506 | 0.430 |
Why?
|
Biomedical Research | 2 | 2016 | 518 | 0.430 |
Why?
|
Retinoblastoma | 4 | 2018 | 110 | 0.430 |
Why?
|
Molecular Sequence Data | 13 | 2015 | 3873 | 0.430 |
Why?
|
DNA Repair | 6 | 2017 | 588 | 0.420 |
Why?
|
MicroRNAs | 2 | 2025 | 840 | 0.420 |
Why?
|
Ribonuclease III | 2 | 2025 | 89 | 0.420 |
Why?
|
Neutropenia | 3 | 2019 | 201 | 0.410 |
Why?
|
Software | 7 | 2018 | 685 | 0.400 |
Why?
|
Saccharomyces cerevisiae Proteins | 4 | 2008 | 276 | 0.390 |
Why?
|
Peroxidase | 2 | 2009 | 62 | 0.390 |
Why?
|
Down Syndrome | 4 | 2023 | 198 | 0.380 |
Why?
|
DNA Repair-Deficiency Disorders | 2 | 2024 | 4 | 0.380 |
Why?
|
Intestinal Polyposis | 2 | 2022 | 17 | 0.380 |
Why?
|
Practice Guidelines as Topic | 7 | 2024 | 1264 | 0.370 |
Why?
|
Gene Dosage | 3 | 2015 | 441 | 0.370 |
Why?
|
DNA Mutational Analysis | 9 | 2019 | 788 | 0.360 |
Why?
|
Meningioma | 2 | 2025 | 120 | 0.360 |
Why?
|
Congenital Abnormalities | 3 | 2025 | 254 | 0.360 |
Why?
|
Carcinoma, Renal Cell | 2 | 2016 | 236 | 0.360 |
Why?
|
Meningeal Neoplasms | 2 | 2025 | 185 | 0.350 |
Why?
|
Risk Management | 1 | 2011 | 68 | 0.350 |
Why?
|
Whole Genome Sequencing | 4 | 2023 | 280 | 0.350 |
Why?
|
DNA Damage | 6 | 2016 | 514 | 0.350 |
Why?
|
Neuroblastoma | 5 | 2023 | 520 | 0.350 |
Why?
|
Receptors, Cell Surface | 2 | 2015 | 469 | 0.340 |
Why?
|
Aneuploidy | 2 | 2010 | 154 | 0.340 |
Why?
|
Texas | 11 | 2024 | 3590 | 0.340 |
Why?
|
Terminology as Topic | 2 | 2024 | 225 | 0.330 |
Why?
|
Medicine | 1 | 2011 | 97 | 0.330 |
Why?
|
Risk Assessment | 8 | 2024 | 3382 | 0.330 |
Why?
|
Fungal Proteins | 2 | 2002 | 134 | 0.330 |
Why?
|
Chromosomes, Human, Pair 8 | 2 | 2007 | 78 | 0.330 |
Why?
|
Transcription, Genetic | 4 | 2005 | 1701 | 0.330 |
Why?
|
Abnormalities, Multiple | 5 | 2017 | 964 | 0.320 |
Why?
|
Glioma | 3 | 2023 | 500 | 0.320 |
Why?
|
Genes, Fungal | 2 | 2008 | 63 | 0.310 |
Why?
|
Telomerase | 2 | 2020 | 160 | 0.310 |
Why?
|
Pediatrics | 2 | 2017 | 1163 | 0.300 |
Why?
|
DNA Mismatch Repair | 3 | 2024 | 48 | 0.300 |
Why?
|
Fanconi Anemia | 2 | 2017 | 44 | 0.300 |
Why?
|
Young Adult | 15 | 2024 | 8979 | 0.300 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 2008 | 40 | 0.300 |
Why?
|
Leukemia, Myeloid | 2 | 2019 | 85 | 0.290 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2008 | 73 | 0.290 |
Why?
|
Carcinoma, Hepatocellular | 4 | 2025 | 938 | 0.290 |
Why?
|
Chromosomal Instability | 1 | 2008 | 58 | 0.290 |
Why?
|
Genes, p53 | 1 | 2008 | 213 | 0.290 |
Why?
|
Models, Theoretical | 1 | 2010 | 358 | 0.290 |
Why?
|
Siblings | 2 | 2024 | 196 | 0.280 |
Why?
|
Anaphase-Promoting Complex-Cyclosome | 4 | 2019 | 20 | 0.280 |
Why?
|
Chromosomes, Human, Pair 7 | 2 | 2005 | 73 | 0.280 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2007 | 92 | 0.280 |
Why?
|
Family | 4 | 2024 | 567 | 0.280 |
Why?
|
Tumor Suppressor Proteins | 4 | 2023 | 467 | 0.280 |
Why?
|
Fanconi Anemia Complementation Group G Protein | 1 | 2006 | 2 | 0.270 |
Why?
|
United States | 19 | 2025 | 10773 | 0.270 |
Why?
|
Mutation, Missense | 4 | 2023 | 868 | 0.270 |
Why?
|
Peroxidases | 1 | 2006 | 26 | 0.270 |
Why?
|
Soft Tissue Neoplasms | 2 | 2021 | 130 | 0.270 |
Why?
|
Gene Deletion | 5 | 2018 | 795 | 0.270 |
Why?
|
Thrombocytopenia | 1 | 2008 | 226 | 0.260 |
Why?
|
MutS Homolog 2 Protein | 3 | 2022 | 40 | 0.260 |
Why?
|
MutL Protein Homolog 1 | 3 | 2022 | 54 | 0.260 |
Why?
|
Risk | 3 | 2021 | 749 | 0.260 |
Why?
|
Ubiquitins | 3 | 2001 | 42 | 0.260 |
Why?
|
Proto-Oncogene Proteins | 4 | 2015 | 549 | 0.250 |
Why?
|
Middle Aged | 21 | 2025 | 26459 | 0.250 |
Why?
|
Chromosome Mapping | 7 | 2023 | 1082 | 0.250 |
Why?
|
Disease Susceptibility | 1 | 2007 | 297 | 0.250 |
Why?
|
Pedigree | 10 | 2016 | 1596 | 0.250 |
Why?
|
Nerve Tissue Proteins | 2 | 2017 | 1114 | 0.250 |
Why?
|
Hematologic Neoplasms | 3 | 2024 | 286 | 0.250 |
Why?
|
Craniofacial Abnormalities | 2 | 2017 | 242 | 0.240 |
Why?
|
Pineal Gland | 1 | 2025 | 19 | 0.240 |
Why?
|
Pinealoma | 1 | 2025 | 21 | 0.240 |
Why?
|
DNA Repair Enzymes | 2 | 2015 | 40 | 0.240 |
Why?
|
Physicians, Family | 2 | 2003 | 37 | 0.240 |
Why?
|
Medical Oncology | 5 | 2018 | 216 | 0.240 |
Why?
|
Multiple Endocrine Neoplasia | 1 | 2025 | 22 | 0.240 |
Why?
|
Evidence-Based Practice | 2 | 2016 | 114 | 0.240 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 2 | 2019 | 39 | 0.240 |
Why?
|
DEAD-box RNA Helicases | 2 | 2025 | 121 | 0.240 |
Why?
|
Syndactyly | 1 | 2005 | 24 | 0.240 |
Why?
|
Genotype | 9 | 2022 | 2552 | 0.240 |
Why?
|
Mass Screening | 3 | 2022 | 784 | 0.240 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 2024 | 27 | 0.240 |
Why?
|
Osteosarcoma | 2 | 2008 | 259 | 0.240 |
Why?
|
Molecular Diagnostic Techniques | 3 | 2016 | 150 | 0.230 |
Why?
|
Language Development Disorders | 2 | 2017 | 173 | 0.230 |
Why?
|
Social Justice | 1 | 2025 | 56 | 0.230 |
Why?
|
Optic Nerve Neoplasms | 1 | 2004 | 19 | 0.230 |
Why?
|
Syndrome | 7 | 2016 | 1124 | 0.230 |
Why?
|
Cell Nucleus | 1 | 2006 | 677 | 0.220 |
Why?
|
Truth Disclosure | 2 | 2017 | 103 | 0.220 |
Why?
|
Conserved Sequence | 3 | 2018 | 293 | 0.220 |
Why?
|
Cell Cycle | 6 | 2019 | 616 | 0.220 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2021 | 1127 | 0.220 |
Why?
|
Pharmacogenomic Variants | 1 | 2023 | 35 | 0.220 |
Why?
|
Beckwith-Wiedemann Syndrome | 1 | 2023 | 16 | 0.220 |
Why?
|
Genome-Wide Association Study | 4 | 2019 | 1660 | 0.220 |
Why?
|
Klinefelter Syndrome | 1 | 2023 | 16 | 0.220 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2023 | 58 | 0.210 |
Why?
|
Risk Factors | 14 | 2025 | 10149 | 0.210 |
Why?
|
Immunoprecipitation | 3 | 2011 | 199 | 0.210 |
Why?
|
DNA | 7 | 2010 | 1598 | 0.210 |
Why?
|
Genomic Instability | 1 | 2024 | 229 | 0.210 |
Why?
|
Myelodysplastic Syndromes | 2 | 2024 | 138 | 0.210 |
Why?
|
Sarcoma | 2 | 2016 | 194 | 0.210 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2025 | 212 | 0.210 |
Why?
|
Growth Disorders | 2 | 2008 | 209 | 0.210 |
Why?
|
Chromosome Breakage | 2 | 2016 | 168 | 0.210 |
Why?
|
Circulating Tumor DNA | 1 | 2023 | 33 | 0.210 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2025 | 534 | 0.210 |
Why?
|
Carcinoma, Small Cell | 1 | 2023 | 50 | 0.210 |
Why?
|
Neoplasms, Second Primary | 2 | 2024 | 152 | 0.210 |
Why?
|
Thyroid Neoplasms | 2 | 2025 | 198 | 0.210 |
Why?
|
Chromatids | 1 | 2002 | 43 | 0.210 |
Why?
|
DNA, Neoplasm | 3 | 2015 | 301 | 0.200 |
Why?
|
Histone Deacetylases | 1 | 2003 | 114 | 0.200 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 89 | 0.200 |
Why?
|
Societies, Medical | 4 | 2018 | 683 | 0.200 |
Why?
|
HeLa Cells | 6 | 2006 | 809 | 0.200 |
Why?
|
Cadherins | 2 | 2022 | 165 | 0.200 |
Why?
|
Loss of Function Mutation | 1 | 2023 | 145 | 0.200 |
Why?
|
Microsatellite Instability | 2 | 2024 | 36 | 0.200 |
Why?
|
Precision Medicine | 6 | 2024 | 315 | 0.200 |
Why?
|
Karyotyping | 4 | 2009 | 330 | 0.200 |
Why?
|
Bloom Syndrome | 2 | 2017 | 5 | 0.200 |
Why?
|
Testicular Neoplasms | 1 | 2023 | 132 | 0.200 |
Why?
|
Reproducibility of Results | 5 | 2019 | 2873 | 0.200 |
Why?
|
Sertoli-Leydig Cell Tumor | 1 | 2022 | 16 | 0.190 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2024 | 848 | 0.190 |
Why?
|
Data Collection | 3 | 2020 | 383 | 0.190 |
Why?
|
Mitochondria | 1 | 2006 | 689 | 0.190 |
Why?
|
Patients | 3 | 2018 | 121 | 0.190 |
Why?
|
MyoD Protein | 1 | 2021 | 21 | 0.190 |
Why?
|
Antigens, CD | 2 | 2022 | 421 | 0.190 |
Why?
|
BRCA2 Protein | 3 | 2020 | 44 | 0.190 |
Why?
|
Multilingualism | 2 | 2018 | 44 | 0.190 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2001 | 64 | 0.190 |
Why?
|
Fibroblasts | 5 | 2016 | 889 | 0.180 |
Why?
|
Incidence | 9 | 2023 | 3086 | 0.180 |
Why?
|
Oxidative Stress | 1 | 2006 | 813 | 0.180 |
Why?
|
Gene Frequency | 5 | 2024 | 719 | 0.180 |
Why?
|
Bone Diseases, Metabolic | 2 | 2014 | 54 | 0.180 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1239 | 0.180 |
Why?
|
Pathologists | 2 | 2018 | 29 | 0.180 |
Why?
|
Trans-Activators | 1 | 2025 | 807 | 0.180 |
Why?
|
Bone Morphogenetic Protein Receptors, Type I | 1 | 2020 | 31 | 0.180 |
Why?
|
Phosphoproteins | 1 | 2002 | 404 | 0.180 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2021 | 887 | 0.180 |
Why?
|
Professional-Family Relations | 2 | 2018 | 94 | 0.180 |
Why?
|
Smad4 Protein | 1 | 2020 | 55 | 0.180 |
Why?
|
Chromosome Aberrations | 2 | 2017 | 621 | 0.170 |
Why?
|
Chromosome Duplication | 2 | 2011 | 147 | 0.170 |
Why?
|
Colectomy | 1 | 2020 | 76 | 0.170 |
Why?
|
Cell Line | 8 | 2019 | 2770 | 0.170 |
Why?
|
Watchful Waiting | 1 | 2020 | 68 | 0.170 |
Why?
|
Chromosomes, Human, Pair 14 | 2 | 2001 | 100 | 0.170 |
Why?
|
Chromosomes, Human, Pair 16 | 2 | 2010 | 150 | 0.170 |
Why?
|
Ependymoma | 1 | 2021 | 134 | 0.170 |
Why?
|
Infant, Newborn | 12 | 2025 | 8184 | 0.170 |
Why?
|
Animals | 14 | 2021 | 34139 | 0.170 |
Why?
|
Transfection | 4 | 2006 | 1069 | 0.170 |
Why?
|
Health Care Surveys | 2 | 2011 | 286 | 0.170 |
Why?
|
Mammography | 1 | 2000 | 114 | 0.170 |
Why?
|
DNA Polymerase II | 1 | 2019 | 19 | 0.170 |
Why?
|
Models, Genetic | 3 | 2018 | 759 | 0.170 |
Why?
|
Health Behavior | 2 | 2014 | 384 | 0.170 |
Why?
|
Apc1 Subunit, Anaphase-Promoting Complex-Cyclosome | 1 | 2019 | 3 | 0.170 |
Why?
|
Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 29 | 0.160 |
Why?
|
Cell Survival | 5 | 2016 | 806 | 0.160 |
Why?
|
Kv Channel-Interacting Proteins | 1 | 2019 | 32 | 0.160 |
Why?
|
Patient Compliance | 2 | 2000 | 473 | 0.160 |
Why?
|
Tandem Repeat Sequences | 2 | 2016 | 37 | 0.160 |
Why?
|
Surveys and Questionnaires | 7 | 2024 | 3733 | 0.160 |
Why?
|
Chromosomes, Human, Pair 12 | 2 | 2015 | 94 | 0.160 |
Why?
|
Attitude of Health Personnel | 2 | 2003 | 673 | 0.160 |
Why?
|
Physicians | 3 | 2018 | 579 | 0.160 |
Why?
|
Nutrition Disorders | 1 | 1999 | 32 | 0.160 |
Why?
|
Telomere Shortening | 1 | 2019 | 33 | 0.160 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 1288 | 0.160 |
Why?
|
Blood Proteins | 1 | 1999 | 116 | 0.160 |
Why?
|
Pyrazoles | 1 | 2021 | 305 | 0.160 |
Why?
|
Vertebrates | 1 | 2018 | 41 | 0.150 |
Why?
|
Cyclic AMP | 1 | 1999 | 248 | 0.150 |
Why?
|
Hepatoblastoma | 2 | 2020 | 180 | 0.150 |
Why?
|
Bone Neoplasms | 1 | 2003 | 430 | 0.150 |
Why?
|
Retinal Neoplasms | 2 | 2011 | 100 | 0.150 |
Why?
|
Sequence Alignment | 3 | 2011 | 625 | 0.150 |
Why?
|
Optic Nerve Glioma | 2 | 2017 | 21 | 0.150 |
Why?
|
Pyrimidines | 1 | 2021 | 374 | 0.150 |
Why?
|
Cell-Free Nucleic Acids | 1 | 2018 | 45 | 0.150 |
Why?
|
Protein Interaction Mapping | 1 | 2018 | 84 | 0.150 |
Why?
|
Empathy | 1 | 2018 | 65 | 0.150 |
Why?
|
Recombinant Fusion Proteins | 3 | 2006 | 767 | 0.150 |
Why?
|
Intensive Care, Neonatal | 1 | 2018 | 53 | 0.150 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2019 | 128 | 0.150 |
Why?
|
Allied Health Personnel | 1 | 2018 | 74 | 0.150 |
Why?
|
Cultural Competency | 1 | 2018 | 51 | 0.150 |
Why?
|
Genetic Privacy | 1 | 2018 | 42 | 0.150 |
Why?
|
Consensus | 2 | 2018 | 629 | 0.140 |
Why?
|
Communication | 2 | 2018 | 516 | 0.140 |
Why?
|
Neurofibromatoses | 1 | 2017 | 7 | 0.140 |
Why?
|
Electronic Health Records | 2 | 2015 | 723 | 0.140 |
Why?
|
Hamartoma Syndrome, Multiple | 1 | 2017 | 20 | 0.140 |
Why?
|
Mitosis | 4 | 2016 | 238 | 0.140 |
Why?
|
Indians, North American | 2 | 2010 | 59 | 0.140 |
Why?
|
Forkhead Transcription Factors | 4 | 2006 | 366 | 0.140 |
Why?
|
Antigens, Nuclear | 1 | 2017 | 61 | 0.140 |
Why?
|
Diagnostic Tests, Routine | 1 | 2018 | 117 | 0.140 |
Why?
|
MAP Kinase Signaling System | 1 | 2019 | 316 | 0.140 |
Why?
|
Child Health Services | 1 | 2018 | 88 | 0.140 |
Why?
|
Language | 1 | 2018 | 204 | 0.140 |
Why?
|
Hodgkin Disease | 2 | 2019 | 293 | 0.140 |
Why?
|
HEK293 Cells | 2 | 2017 | 753 | 0.140 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2017 | 41 | 0.140 |
Why?
|
Neurilemmoma | 1 | 2017 | 48 | 0.140 |
Why?
|
G2 Phase | 4 | 2006 | 45 | 0.140 |
Why?
|
Genetic Linkage | 2 | 2015 | 452 | 0.140 |
Why?
|
Chromosomes, Human, Pair 17 | 2 | 2015 | 370 | 0.140 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2016 | 554 | 0.140 |
Why?
|
Bone Diseases, Developmental | 1 | 2017 | 58 | 0.140 |
Why?
|
Stomach Neoplasms | 1 | 2022 | 540 | 0.130 |
Why?
|
Hypertrophy | 1 | 2017 | 101 | 0.130 |
Why?
|
Practice Patterns, Physicians' | 1 | 2003 | 720 | 0.130 |
Why?
|
B-Lymphocytes | 2 | 2016 | 525 | 0.130 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 98 | 0.130 |
Why?
|
Medical History Taking | 2 | 2020 | 106 | 0.130 |
Why?
|
Age Factors | 4 | 2020 | 2805 | 0.130 |
Why?
|
Microcephaly | 2 | 2017 | 332 | 0.130 |
Why?
|
Feeding and Eating Disorders | 1 | 2017 | 70 | 0.130 |
Why?
|
Phylogeny | 1 | 2018 | 696 | 0.130 |
Why?
|
Two-Hybrid System Techniques | 2 | 2006 | 66 | 0.130 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2016 | 24 | 0.130 |
Why?
|
Boronic Acids | 2 | 2007 | 48 | 0.130 |
Why?
|
Gene Expression Profiling | 4 | 2021 | 1695 | 0.130 |
Why?
|
Glutathione Transferase | 2 | 2009 | 153 | 0.130 |
Why?
|
Limb Deformities, Congenital | 1 | 2017 | 106 | 0.130 |
Why?
|
Registries | 5 | 2025 | 1411 | 0.130 |
Why?
|
Medulloblastoma | 1 | 2019 | 340 | 0.130 |
Why?
|
Infant, Newborn, Diseases | 1 | 2018 | 171 | 0.130 |
Why?
|
Pyrazines | 2 | 2007 | 73 | 0.130 |
Why?
|
Haploinsufficiency | 1 | 2017 | 257 | 0.130 |
Why?
|
Apoptosis | 1 | 2002 | 1789 | 0.130 |
Why?
|
National Human Genome Research Institute (U.S.) | 4 | 2018 | 17 | 0.130 |
Why?
|
Sarcoma, Clear Cell | 1 | 2015 | 20 | 0.130 |
Why?
|
Multiplex Polymerase Chain Reaction | 1 | 2015 | 29 | 0.130 |
Why?
|
Zonula Occludens-2 Protein | 1 | 2015 | 7 | 0.130 |
Why?
|
Amino Acid Metabolism, Inborn Errors | 1 | 2016 | 98 | 0.130 |
Why?
|
Amino Acid Sequence | 5 | 2006 | 2699 | 0.130 |
Why?
|
Plasmids | 4 | 2005 | 514 | 0.120 |
Why?
|
Pathology, Molecular | 1 | 2015 | 58 | 0.120 |
Why?
|
Cohort Studies | 6 | 2024 | 4734 | 0.120 |
Why?
|
Prognosis | 5 | 2020 | 4554 | 0.120 |
Why?
|
Interview, Psychological | 1 | 2015 | 98 | 0.120 |
Why?
|
Cholestasis, Intrahepatic | 1 | 2016 | 58 | 0.120 |
Why?
|
Parenting | 1 | 2019 | 332 | 0.120 |
Why?
|
DCC Receptor | 1 | 2015 | 5 | 0.120 |
Why?
|
Telomere | 1 | 2016 | 208 | 0.120 |
Why?
|
DNA, Complementary | 3 | 2003 | 464 | 0.120 |
Why?
|
History, 20th Century | 1 | 2017 | 384 | 0.120 |
Why?
|
Information Storage and Retrieval | 1 | 2015 | 59 | 0.120 |
Why?
|
Open Reading Frames | 2 | 2010 | 210 | 0.120 |
Why?
|
Data Interpretation, Statistical | 1 | 2016 | 231 | 0.120 |
Why?
|
Chromosome Breakpoints | 1 | 2015 | 80 | 0.120 |
Why?
|
Oncogene Fusion | 1 | 2014 | 22 | 0.120 |
Why?
|
Ophthalmology | 1 | 2017 | 198 | 0.120 |
Why?
|
Cyclin B | 1 | 2014 | 23 | 0.120 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 2015 | 62 | 0.120 |
Why?
|
Chromosome Disorders | 1 | 2017 | 312 | 0.120 |
Why?
|
Central Nervous System Neoplasms | 1 | 2017 | 197 | 0.120 |
Why?
|
Retrospective Studies | 7 | 2024 | 16233 | 0.120 |
Why?
|
INDEL Mutation | 1 | 2015 | 87 | 0.120 |
Why?
|
Aged | 10 | 2020 | 19479 | 0.120 |
Why?
|
Protein Conformation | 2 | 2016 | 833 | 0.120 |
Why?
|
Telomere-Binding Proteins | 1 | 2014 | 43 | 0.120 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2020 | 35 | 0.110 |
Why?
|
Ubiquitin-Conjugating Enzymes | 3 | 2001 | 39 | 0.110 |
Why?
|
Biomarkers, Tumor | 3 | 2023 | 1460 | 0.110 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2015 | 119 | 0.110 |
Why?
|
Neutrophils | 1 | 2016 | 378 | 0.110 |
Why?
|
Lymphedema | 1 | 2014 | 19 | 0.110 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2015 | 141 | 0.110 |
Why?
|
RNA, Messenger | 3 | 2015 | 2824 | 0.110 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2009 | 764 | 0.110 |
Why?
|
Genes, Dominant | 2 | 2013 | 247 | 0.110 |
Why?
|
Genes, Recessive | 2 | 2013 | 179 | 0.110 |
Why?
|
PAX5 Transcription Factor | 1 | 2013 | 13 | 0.110 |
Why?
|
Prospective Studies | 3 | 2024 | 6089 | 0.110 |
Why?
|
Intensive Care Units, Pediatric | 1 | 2017 | 479 | 0.110 |
Why?
|
Retinoblastoma Protein | 2 | 2011 | 78 | 0.110 |
Why?
|
Comparative Genomic Hybridization | 2 | 2012 | 573 | 0.110 |
Why?
|
Adenoma | 1 | 2015 | 135 | 0.110 |
Why?
|
Genes, Tumor Suppressor | 2 | 2011 | 204 | 0.110 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2013 | 37 | 0.100 |
Why?
|
Muscle Hypotonia | 1 | 2014 | 188 | 0.100 |
Why?
|
Sleep Apnea Syndromes | 1 | 2014 | 74 | 0.100 |
Why?
|
DNA Primers | 4 | 2011 | 660 | 0.100 |
Why?
|
Support Vector Machine | 1 | 2012 | 19 | 0.100 |
Why?
|
Penetrance | 3 | 2018 | 103 | 0.100 |
Why?
|
Proteins | 1 | 2018 | 1043 | 0.100 |
Why?
|
Osteoporosis | 1 | 2014 | 116 | 0.100 |
Why?
|
Intestinal Neoplasms | 1 | 2013 | 39 | 0.100 |
Why?
|
Age of Onset | 3 | 2024 | 582 | 0.100 |
Why?
|
Longitudinal Studies | 3 | 2019 | 1333 | 0.100 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 389 | 0.100 |
Why?
|
Models, Molecular | 1 | 2016 | 1074 | 0.100 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2017 | 1000 | 0.100 |
Why?
|
Attitude | 1 | 2013 | 114 | 0.100 |
Why?
|
Ultraviolet Rays | 3 | 2008 | 204 | 0.100 |
Why?
|
Lung Diseases | 1 | 2016 | 383 | 0.100 |
Why?
|
Health Surveys | 1 | 2013 | 244 | 0.100 |
Why?
|
Polymerase Chain Reaction | 3 | 2015 | 1584 | 0.100 |
Why?
|
Sequence Homology, Amino Acid | 3 | 2006 | 657 | 0.100 |
Why?
|
Patient Education as Topic | 3 | 2002 | 443 | 0.100 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 128 | 0.100 |
Why?
|
Mismatch Repair Endonuclease PMS2 | 3 | 2017 | 9 | 0.100 |
Why?
|
Medical Informatics | 1 | 2013 | 108 | 0.100 |
Why?
|
Promoter Regions, Genetic | 3 | 2009 | 1341 | 0.100 |
Why?
|
Mutagenicity Tests | 2 | 2008 | 36 | 0.100 |
Why?
|
Histones | 3 | 2011 | 534 | 0.100 |
Why?
|
Genes, Retinoblastoma | 1 | 2011 | 18 | 0.100 |
Why?
|
Research Personnel | 1 | 2013 | 118 | 0.100 |
Why?
|
Ubiquitin-Protein Ligases | 3 | 2001 | 356 | 0.090 |
Why?
|
DNA Replication | 3 | 2024 | 350 | 0.090 |
Why?
|
Health Services Needs and Demand | 1 | 2012 | 174 | 0.090 |
Why?
|
Ganglioglioma | 1 | 2011 | 24 | 0.090 |
Why?
|
Oncogenes | 2 | 2011 | 168 | 0.090 |
Why?
|
Decision Support Systems, Clinical | 1 | 2013 | 171 | 0.090 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2011 | 106 | 0.090 |
Why?
|
Membrane Proteins | 2 | 2017 | 1529 | 0.090 |
Why?
|
Cell Line, Tumor | 3 | 2006 | 3341 | 0.090 |
Why?
|
Intestine, Small | 1 | 2013 | 313 | 0.090 |
Why?
|
Rhabdoid Tumor | 1 | 2011 | 50 | 0.090 |
Why?
|
Referral and Consultation | 4 | 2014 | 539 | 0.090 |
Why?
|
Proportional Hazards Models | 3 | 2025 | 1320 | 0.090 |
Why?
|
Costs and Cost Analysis | 1 | 2011 | 164 | 0.090 |
Why?
|
Organisms, Genetically Modified | 1 | 2010 | 11 | 0.090 |
Why?
|
Tumor Cells, Cultured | 5 | 2005 | 1064 | 0.090 |
Why?
|
Enzyme Inhibitors | 2 | 2003 | 578 | 0.080 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2011 | 158 | 0.080 |
Why?
|
Skin Neoplasms | 1 | 2017 | 803 | 0.080 |
Why?
|
Mutagenesis, Insertional | 2 | 2008 | 147 | 0.080 |
Why?
|
Glutathione S-Transferase pi | 1 | 2009 | 25 | 0.080 |
Why?
|
Metabolism, Inborn Errors | 1 | 2011 | 114 | 0.080 |
Why?
|
Globins | 2 | 1986 | 35 | 0.080 |
Why?
|
Genes, Regulator | 2 | 1986 | 56 | 0.080 |
Why?
|
Immunohistochemistry | 4 | 2015 | 1684 | 0.080 |
Why?
|
Heart Diseases | 1 | 2014 | 485 | 0.080 |
Why?
|
Pilot Projects | 3 | 2018 | 1404 | 0.080 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2010 | 133 | 0.080 |
Why?
|
Protein Array Analysis | 1 | 2009 | 101 | 0.080 |
Why?
|
Zinc Fingers | 1 | 2009 | 121 | 0.080 |
Why?
|
Clinical Laboratory Techniques | 1 | 2010 | 141 | 0.080 |
Why?
|
Europe | 3 | 2018 | 352 | 0.080 |
Why?
|
Simian virus 40 | 2 | 1986 | 197 | 0.080 |
Why?
|
Translating | 2 | 2018 | 31 | 0.080 |
Why?
|
Signal Transduction | 3 | 2017 | 4534 | 0.080 |
Why?
|
Phosphorylation | 3 | 2017 | 1625 | 0.080 |
Why?
|
Kinetochores | 1 | 2008 | 12 | 0.070 |
Why?
|
Erythropoiesis | 1 | 2008 | 40 | 0.070 |
Why?
|
Chromosomes, Fungal | 1 | 2008 | 49 | 0.070 |
Why?
|
Mutagens | 1 | 2008 | 84 | 0.070 |
Why?
|
Megakaryocytes | 1 | 2008 | 43 | 0.070 |
Why?
|
Clone Cells | 1 | 2008 | 167 | 0.070 |
Why?
|
Prevalence | 3 | 2018 | 2433 | 0.070 |
Why?
|
Acid Anhydride Hydrolases | 1 | 2007 | 7 | 0.070 |
Why?
|
Enhancer Elements, Genetic | 2 | 1986 | 295 | 0.070 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 1996 | 826 | 0.070 |
Why?
|
Nucleic Acid Hybridization | 1 | 2008 | 395 | 0.070 |
Why?
|
Janus Kinase 2 | 1 | 2008 | 134 | 0.070 |
Why?
|
Drug Resistance | 1 | 2008 | 256 | 0.070 |
Why?
|
Chromosomes, Artificial, Bacterial | 1 | 2007 | 93 | 0.070 |
Why?
|
Point Mutation | 1 | 2008 | 348 | 0.070 |
Why?
|
Cisplatin | 2 | 2008 | 242 | 0.070 |
Why?
|
Demography | 2 | 1999 | 240 | 0.070 |
Why?
|
Nuclear Localization Signals | 1 | 2006 | 16 | 0.070 |
Why?
|
Peroxiredoxin III | 1 | 2006 | 2 | 0.070 |
Why?
|
DNA Transposable Elements | 1 | 2008 | 177 | 0.070 |
Why?
|
Peroxiredoxins | 1 | 2006 | 9 | 0.070 |
Why?
|
Sequence Analysis | 2 | 2019 | 54 | 0.070 |
Why?
|
Multiple Endocrine Neoplasia Type 1 | 1 | 2006 | 5 | 0.070 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2006 | 65 | 0.070 |
Why?
|
Mitomycin | 1 | 2006 | 49 | 0.070 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2006 | 117 | 0.070 |
Why?
|
Calpain | 1 | 2006 | 41 | 0.070 |
Why?
|
Gene Expression | 3 | 2001 | 1569 | 0.070 |
Why?
|
DNA Topoisomerases, Type II | 1 | 1986 | 22 | 0.070 |
Why?
|
Physician-Patient Relations | 3 | 2018 | 426 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2010 | 619 | 0.070 |
Why?
|
COS Cells | 1 | 2006 | 276 | 0.070 |
Why?
|
Cells, Cultured | 3 | 2017 | 3050 | 0.070 |
Why?
|
Hydrogen Peroxide | 1 | 2006 | 113 | 0.070 |
Why?
|
Exons | 2 | 2016 | 796 | 0.060 |
Why?
|
Son of Sevenless Proteins | 1 | 2005 | 5 | 0.060 |
Why?
|
Aged, 80 and over | 4 | 2019 | 6470 | 0.060 |
Why?
|
Fluorescent Antibody Technique | 1 | 2006 | 459 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2009 | 1015 | 0.060 |
Why?
|
Ubiquitin | 1 | 2006 | 142 | 0.060 |
Why?
|
Cell Division | 3 | 2006 | 781 | 0.060 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2006 | 127 | 0.060 |
Why?
|
Cytoplasm | 1 | 2006 | 291 | 0.060 |
Why?
|
Oxidation-Reduction | 1 | 2006 | 445 | 0.060 |
Why?
|
Survival Analysis | 1 | 2009 | 1482 | 0.060 |
Why?
|
Luciferases | 1 | 2005 | 135 | 0.060 |
Why?
|
Genetic Markers | 2 | 1998 | 606 | 0.060 |
Why?
|
Microscopy, Fluorescence | 1 | 2006 | 328 | 0.060 |
Why?
|
Green Fluorescent Proteins | 1 | 2006 | 391 | 0.060 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2003 | 66 | 0.060 |
Why?
|
Radius | 1 | 2005 | 25 | 0.060 |
Why?
|
Gene Regulatory Networks | 1 | 2008 | 355 | 0.060 |
Why?
|
Cloning, Molecular | 2 | 1999 | 892 | 0.060 |
Why?
|
Lymphoma | 1 | 2008 | 322 | 0.060 |
Why?
|
Protease Inhibitors | 1 | 2005 | 93 | 0.060 |
Why?
|
Zinc Finger Protein Gli3 | 1 | 2005 | 7 | 0.060 |
Why?
|
Heart Defects, Congenital | 1 | 2017 | 1817 | 0.060 |
Why?
|
Nuclear Receptor Coactivators | 1 | 2005 | 72 | 0.060 |
Why?
|
Ikaros Transcription Factor | 1 | 2005 | 28 | 0.060 |
Why?
|
Disease Management | 2 | 2019 | 519 | 0.060 |
Why?
|
Lymphocytes | 1 | 2006 | 406 | 0.060 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2015 | 1244 | 0.060 |
Why?
|
DNA Methylation | 1 | 2011 | 1002 | 0.060 |
Why?
|
Informed Consent | 2 | 2018 | 336 | 0.060 |
Why?
|
Amino Acid Substitution | 2 | 2020 | 393 | 0.060 |
Why?
|
Binding Sites | 2 | 2006 | 1294 | 0.060 |
Why?
|
Colonoscopy | 2 | 2020 | 240 | 0.060 |
Why?
|
Cyclin D1 | 1 | 2004 | 112 | 0.060 |
Why?
|
Motivation | 2 | 2013 | 314 | 0.060 |
Why?
|
Cost-Benefit Analysis | 2 | 2018 | 511 | 0.060 |
Why?
|
Acute Disease | 2 | 2018 | 1101 | 0.060 |
Why?
|
Cyclins | 1 | 2004 | 101 | 0.060 |
Why?
|
Logistic Models | 2 | 1999 | 1804 | 0.060 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2005 | 109 | 0.060 |
Why?
|
Family Health | 3 | 2016 | 259 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2020 | 5107 | 0.060 |
Why?
|
Sin3 Histone Deacetylase and Corepressor Complex | 1 | 2003 | 5 | 0.050 |
Why?
|
Checkpoint Kinase 2 | 1 | 2003 | 36 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2007 | 1687 | 0.050 |
Why?
|
Cell Proliferation | 3 | 2017 | 2304 | 0.050 |
Why?
|
Spindle Apparatus | 1 | 2003 | 63 | 0.050 |
Why?
|
Anxiety | 2 | 2000 | 966 | 0.050 |
Why?
|
Blotting, Southern | 1 | 2003 | 215 | 0.050 |
Why?
|
Bone Marrow Cells | 1 | 2005 | 261 | 0.050 |
Why?
|
Blotting, Western | 1 | 2005 | 1108 | 0.050 |
Why?
|
Proteasome Endopeptidase Complex | 2 | 2007 | 266 | 0.050 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 2002 | 13 | 0.050 |
Why?
|
Mice | 4 | 2021 | 17725 | 0.050 |
Why?
|
Craniosynostoses | 1 | 2005 | 132 | 0.050 |
Why?
|
Caspase Inhibitors | 1 | 2002 | 31 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 3 | 2017 | 3578 | 0.050 |
Why?
|
Prostaglandins | 1 | 2002 | 48 | 0.050 |
Why?
|
In Situ Nick-End Labeling | 1 | 2002 | 124 | 0.050 |
Why?
|
Minority Groups | 1 | 2024 | 251 | 0.050 |
Why?
|
Diseases in Twins | 1 | 2003 | 94 | 0.050 |
Why?
|
Etoposide | 1 | 2002 | 117 | 0.050 |
Why?
|
Temperature | 1 | 2003 | 304 | 0.050 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2016 | 152 | 0.050 |
Why?
|
Larva | 2 | 2017 | 248 | 0.050 |
Why?
|
3T3 Cells | 1 | 2002 | 129 | 0.050 |
Why?
|
Prostatic Neoplasms | 1 | 2011 | 1531 | 0.050 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2002 | 317 | 0.050 |
Why?
|
Caspases | 1 | 2002 | 162 | 0.050 |
Why?
|
Genes, myc | 1 | 2002 | 99 | 0.050 |
Why?
|
Receptor, trkB | 1 | 2021 | 20 | 0.050 |
Why?
|
Calcium-Binding Proteins | 1 | 2023 | 324 | 0.050 |
Why?
|
Cell Nucleolus | 1 | 2001 | 56 | 0.050 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 2001 | 30 | 0.050 |
Why?
|
Immunoblotting | 2 | 2015 | 313 | 0.050 |
Why?
|
Protein Binding | 1 | 2005 | 1747 | 0.050 |
Why?
|
Recombination, Genetic | 2 | 2016 | 447 | 0.050 |
Why?
|
Cytogenetic Analysis | 1 | 2001 | 79 | 0.050 |
Why?
|
Virulence | 1 | 2022 | 262 | 0.050 |
Why?
|
Introns | 1 | 2002 | 300 | 0.050 |
Why?
|
Reference Values | 2 | 2001 | 709 | 0.050 |
Why?
|
Likelihood Functions | 2 | 2013 | 111 | 0.050 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 2001 | 118 | 0.050 |
Why?
|
Microsatellite Repeats | 2 | 2005 | 219 | 0.050 |
Why?
|
Trisomy | 1 | 2001 | 103 | 0.050 |
Why?
|
RNA Splicing | 1 | 2002 | 226 | 0.040 |
Why?
|
Quinolines | 1 | 2021 | 96 | 0.040 |
Why?
|
Succinate Dehydrogenase | 1 | 2020 | 7 | 0.040 |
Why?
|
Fanconi Anemia Complementation Group Proteins | 1 | 2020 | 9 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2016 | 1017 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2023 | 767 | 0.040 |
Why?
|
Patient Participation | 1 | 2023 | 222 | 0.040 |
Why?
|
Imidazoles | 1 | 2021 | 194 | 0.040 |
Why?
|
Gene Expression Regulation | 2 | 2005 | 2534 | 0.040 |
Why?
|
Homozygote | 2 | 2016 | 533 | 0.040 |
Why?
|
Ataxia Telangiectasia Mutated Proteins | 1 | 2020 | 94 | 0.040 |
Why?
|
Burkitt Lymphoma | 1 | 2001 | 146 | 0.040 |
Why?
|
RNA Helicases | 1 | 2020 | 63 | 0.040 |
Why?
|
Activating Transcription Factors | 1 | 1999 | 4 | 0.040 |
Why?
|
Time Factors | 3 | 2011 | 6272 | 0.040 |
Why?
|
Cyclic AMP Response Element Modulator | 1 | 1999 | 25 | 0.040 |
Why?
|
Marfan Syndrome | 1 | 2001 | 139 | 0.040 |
Why?
|
Test Anxiety Scale | 1 | 1999 | 2 | 0.040 |
Why?
|
Microfilament Proteins | 1 | 2001 | 274 | 0.040 |
Why?
|
Occult Blood | 1 | 1999 | 33 | 0.040 |
Why?
|
Peptides | 1 | 2002 | 793 | 0.040 |
Why?
|
Wasting Syndrome | 1 | 1999 | 25 | 0.040 |
Why?
|
Social Responsibility | 1 | 2019 | 80 | 0.040 |
Why?
|
Lymphocyte Activation | 1 | 2001 | 688 | 0.040 |
Why?
|
Linguistics | 1 | 2018 | 18 | 0.040 |
Why?
|
Multienzyme Complexes | 1 | 1999 | 90 | 0.040 |
Why?
|
Membrane Glycoproteins | 1 | 2021 | 412 | 0.040 |
Why?
|
Alternative Splicing | 1 | 2001 | 350 | 0.040 |
Why?
|
Cysteine Endopeptidases | 1 | 1999 | 114 | 0.040 |
Why?
|
Endopeptidases | 1 | 1999 | 113 | 0.040 |
Why?
|
Diploidy | 2 | 2008 | 35 | 0.040 |
Why?
|
Communication Barriers | 1 | 2018 | 39 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2024 | 605 | 0.040 |
Why?
|
Genetic Carrier Screening | 1 | 1998 | 68 | 0.040 |
Why?
|
Physical Examination | 1 | 1999 | 163 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2018 | 29 | 0.040 |
Why?
|
Confidentiality | 1 | 1999 | 99 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2018 | 28 | 0.040 |
Why?
|
Case-Control Studies | 2 | 2015 | 3268 | 0.040 |
Why?
|
Parental Consent | 1 | 2018 | 23 | 0.040 |
Why?
|
Spermatogenesis | 1 | 1999 | 171 | 0.040 |
Why?
|
Computer Security | 1 | 2018 | 26 | 0.040 |
Why?
|
Kinetics | 2 | 1997 | 1321 | 0.040 |
Why?
|
Intention | 1 | 2018 | 92 | 0.040 |
Why?
|
Body Height | 1 | 1999 | 214 | 0.040 |
Why?
|
Infant Care | 1 | 2017 | 46 | 0.040 |
Why?
|
Loss of Heterozygosity | 1 | 2018 | 124 | 0.040 |
Why?
|
Physician's Role | 1 | 1999 | 165 | 0.040 |
Why?
|
Social Behavior | 1 | 2019 | 209 | 0.040 |
Why?
|
Xeroderma Pigmentosum | 1 | 2017 | 8 | 0.040 |
Why?
|
Clinical Decision-Making | 1 | 2019 | 267 | 0.040 |
Why?
|
Guatemala | 1 | 2017 | 62 | 0.040 |
Why?
|
Ataxia Telangiectasia | 1 | 2017 | 15 | 0.040 |
Why?
|
Washington | 1 | 2017 | 33 | 0.040 |
Why?
|
GTP-Binding Protein beta Subunits | 1 | 2017 | 31 | 0.030 |
Why?
|
Power Plants | 1 | 1997 | 1 | 0.030 |
Why?
|
Radioactive Fallout | 1 | 1997 | 1 | 0.030 |
Why?
|
Radioactive Hazard Release | 1 | 1997 | 1 | 0.030 |
Why?
|
Leukemia, Radiation-Induced | 1 | 1997 | 2 | 0.030 |
Why?
|
Germany | 1 | 1997 | 66 | 0.030 |
Why?
|
ATPases Associated with Diverse Cellular Activities | 1 | 2017 | 67 | 0.030 |
Why?
|
Radiotherapy | 2 | 2014 | 136 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2002 | 2030 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 1997 | 52 | 0.030 |
Why?
|
Philadelphia Chromosome | 1 | 2017 | 40 | 0.030 |
Why?
|
Eye | 1 | 2018 | 227 | 0.030 |
Why?
|
Nutritional Status | 1 | 1999 | 312 | 0.030 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2017 | 120 | 0.030 |
Why?
|
Metalloendopeptidases | 1 | 2017 | 100 | 0.030 |
Why?
|
Sample Size | 1 | 2016 | 85 | 0.030 |
Why?
|
Genotyping Techniques | 1 | 2016 | 103 | 0.030 |
Why?
|
Everolimus | 1 | 2016 | 46 | 0.030 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 1997 | 81 | 0.030 |
Why?
|
Cerebellar Neoplasms | 1 | 2019 | 285 | 0.030 |
Why?
|
Population Groups | 1 | 2016 | 30 | 0.030 |
Why?
|
Chromosome Segregation | 1 | 2016 | 62 | 0.030 |
Why?
|
Carrier Proteins | 1 | 2001 | 1024 | 0.030 |
Why?
|
Research Report | 1 | 2016 | 70 | 0.030 |
Why?
|
Bortezomib | 2 | 2007 | 73 | 0.030 |
Why?
|
Meiosis | 1 | 2016 | 115 | 0.030 |
Why?
|
Mutagenesis | 1 | 1997 | 347 | 0.030 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2024 | 1199 | 0.030 |
Why?
|
Remission Induction | 1 | 2016 | 301 | 0.030 |
Why?
|
Chromosomes | 1 | 2016 | 199 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2019 | 2896 | 0.030 |
Why?
|
Mitochondrial Proteins | 1 | 2017 | 237 | 0.030 |
Why?
|
National Library of Medicine (U.S.) | 1 | 2015 | 5 | 0.030 |
Why?
|
Health Care Costs | 1 | 2018 | 368 | 0.030 |
Why?
|
Templates, Genetic | 1 | 1995 | 97 | 0.030 |
Why?
|
Radiation-Sensitizing Agents | 1 | 1995 | 25 | 0.030 |
Why?
|
Utah | 1 | 2015 | 46 | 0.030 |
Why?
|
Gene Editing | 1 | 2017 | 193 | 0.030 |
Why?
|
Inhibitory Concentration 50 | 2 | 2005 | 77 | 0.030 |
Why?
|
Epigenomics | 1 | 2016 | 164 | 0.030 |
Why?
|
Oligodendroglioma | 1 | 2014 | 24 | 0.030 |
Why?
|
Sirolimus | 1 | 2016 | 221 | 0.030 |
Why?
|
Zebrafish | 1 | 2017 | 389 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2016 | 235 | 0.030 |
Why?
|
G1 Phase | 1 | 1995 | 67 | 0.030 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2016 | 188 | 0.030 |
Why?
|
CRISPR-Cas Systems | 1 | 2017 | 261 | 0.030 |
Why?
|
Body Weight | 1 | 1999 | 1005 | 0.030 |
Why?
|
Caffeine | 1 | 1995 | 70 | 0.030 |
Why?
|
Recombinant Proteins | 3 | 2006 | 1392 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2016 | 426 | 0.030 |
Why?
|
Genetic Complementation Test | 1 | 1993 | 87 | 0.030 |
Why?
|
Gene Duplication | 1 | 2015 | 358 | 0.030 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 1993 | 59 | 0.030 |
Why?
|
Health Personnel | 1 | 2018 | 507 | 0.030 |
Why?
|
Bile Acids and Salts | 1 | 2016 | 245 | 0.030 |
Why?
|
Genes, X-Linked | 1 | 2013 | 59 | 0.030 |
Why?
|
Disease Progression | 1 | 2019 | 2042 | 0.030 |
Why?
|
Lymph Node Excision | 1 | 2014 | 157 | 0.030 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2013 | 133 | 0.030 |
Why?
|
Access to Information | 1 | 2013 | 40 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2014 | 376 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2015 | 375 | 0.030 |
Why?
|
Workflow | 1 | 2013 | 117 | 0.030 |
Why?
|
Body Mass Index | 1 | 1999 | 1550 | 0.030 |
Why?
|
Delivery of Health Care | 1 | 2018 | 606 | 0.030 |
Why?
|
Intussusception | 1 | 2013 | 46 | 0.030 |
Why?
|
Genes | 1 | 1993 | 444 | 0.030 |
Why?
|
Expert Testimony | 1 | 2012 | 36 | 0.030 |
Why?
|
Gene Order | 1 | 2012 | 79 | 0.030 |
Why?
|
Probability | 1 | 2013 | 323 | 0.030 |
Why?
|
Population Surveillance | 1 | 2015 | 389 | 0.030 |
Why?
|
Recurrence | 1 | 2016 | 1423 | 0.020 |
Why?
|
Patient Preference | 1 | 2013 | 119 | 0.020 |
Why?
|
Critical Care | 1 | 2017 | 650 | 0.020 |
Why?
|
Inheritance Patterns | 1 | 2012 | 124 | 0.020 |
Why?
|
Length of Stay | 1 | 2017 | 1308 | 0.020 |
Why?
|
Eye Enucleation | 1 | 2011 | 54 | 0.020 |
Why?
|
Odds Ratio | 1 | 2015 | 1246 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2016 | 1085 | 0.020 |
Why?
|
TNF Receptor-Associated Factor 2 | 1 | 2011 | 8 | 0.020 |
Why?
|
Survivors | 1 | 2014 | 344 | 0.020 |
Why?
|
Sex Factors | 2 | 2008 | 1267 | 0.020 |
Why?
|
Qualitative Research | 1 | 2014 | 548 | 0.020 |
Why?
|
Sequence Analysis, Protein | 1 | 2011 | 49 | 0.020 |
Why?
|
Fetus | 1 | 2014 | 584 | 0.020 |
Why?
|
Segmental Duplications, Genomic | 1 | 2010 | 81 | 0.020 |
Why?
|
Pregnancy | 2 | 2018 | 7167 | 0.020 |
Why?
|
Models, Statistical | 1 | 2013 | 472 | 0.020 |
Why?
|
Prostate-Specific Antigen | 1 | 2011 | 256 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 1999 | 4425 | 0.020 |
Why?
|
Adrenal Glands | 1 | 1990 | 43 | 0.020 |
Why?
|
Databases, Factual | 1 | 2015 | 1174 | 0.020 |
Why?
|
Metabolic Networks and Pathways | 1 | 2011 | 188 | 0.020 |
Why?
|
Breast | 1 | 2011 | 215 | 0.020 |
Why?
|
DNA, Mitochondrial | 1 | 2011 | 211 | 0.020 |
Why?
|
DNA, Recombinant | 2 | 1986 | 100 | 0.020 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2011 | 510 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2017 | 3753 | 0.020 |
Why?
|
Nucleic Acid Conformation | 2 | 1986 | 184 | 0.020 |
Why?
|
Colony Count, Microbial | 1 | 2008 | 89 | 0.020 |
Why?
|
4-Nitroquinoline-1-oxide | 1 | 2008 | 8 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2008 | 96 | 0.020 |
Why?
|
Radiation, Ionizing | 1 | 2008 | 41 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2008 | 279 | 0.020 |
Why?
|
Camptothecin | 1 | 2008 | 76 | 0.020 |
Why?
|
Parathyroid Hormone | 1 | 2008 | 72 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2016 | 1697 | 0.020 |
Why?
|
Hydroxyurea | 1 | 2008 | 82 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 2008 | 178 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2008 | 623 | 0.020 |
Why?
|
Patient Care Team | 1 | 2011 | 546 | 0.020 |
Why?
|
Neurons | 1 | 2017 | 1964 | 0.020 |
Why?
|
I-kappa B Kinase | 1 | 2007 | 61 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2007 | 158 | 0.020 |
Why?
|
Doxorubicin | 1 | 2008 | 301 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2008 | 860 | 0.020 |
Why?
|
Trioxsalen | 1 | 1986 | 2 | 0.020 |
Why?
|
Furocoumarins | 1 | 1986 | 3 | 0.020 |
Why?
|
Genes, Synthetic | 1 | 1986 | 11 | 0.020 |
Why?
|
DNA, Superhelical | 1 | 1986 | 20 | 0.020 |
Why?
|
Models, Biological | 1 | 2011 | 1459 | 0.020 |
Why?
|
Developmental Disabilities | 1 | 2010 | 708 | 0.020 |
Why?
|
Bone Density | 1 | 2008 | 319 | 0.020 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2005 | 75 | 0.020 |
Why?
|
Ki-67 Antigen | 1 | 2005 | 113 | 0.020 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2005 | 286 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 172 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 816 | 0.010 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2005 | 107 | 0.010 |
Why?
|
Cyclin D3 | 1 | 2004 | 10 | 0.010 |
Why?
|
Drug Interactions | 1 | 2005 | 253 | 0.010 |
Why?
|
Cyclin D2 | 1 | 2004 | 14 | 0.010 |
Why?
|
Heat-Shock Proteins | 1 | 2005 | 195 | 0.010 |
Why?
|
NF-kappa B | 1 | 2007 | 459 | 0.010 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2004 | 41 | 0.010 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2005 | 344 | 0.010 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2004 | 57 | 0.010 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2004 | 86 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2016 | 1888 | 0.010 |
Why?
|
Escherichia coli | 1 | 2008 | 987 | 0.010 |
Why?
|
Calcium | 1 | 2008 | 1095 | 0.010 |
Why?
|
Minichromosome Maintenance Complex Component 7 | 1 | 2002 | 5 | 0.010 |
Why?
|
Horseshoe Crabs | 1 | 1982 | 1 | 0.010 |
Why?
|
Hemocyanins | 1 | 1982 | 27 | 0.010 |
Why?
|
Interphase | 1 | 2001 | 45 | 0.010 |
Why?
|
HL-60 Cells | 1 | 2001 | 32 | 0.010 |
Why?
|
Jurkat Cells | 1 | 2001 | 77 | 0.010 |
Why?
|
K562 Cells | 1 | 2001 | 95 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 2001 | 169 | 0.010 |
Why?
|
Copper | 1 | 1982 | 63 | 0.010 |
Why?
|
Fibrillins | 1 | 2001 | 31 | 0.010 |
Why?
|
Fibrillin-1 | 1 | 2001 | 58 | 0.010 |
Why?
|
Gene Amplification | 1 | 2002 | 228 | 0.010 |
Why?
|
Drosophila melanogaster | 1 | 2006 | 771 | 0.010 |
Why?
|
Rabbits | 1 | 2001 | 711 | 0.010 |
Why?
|
Drosophila Proteins | 1 | 2006 | 723 | 0.010 |
Why?
|
Frameshift Mutation | 1 | 2001 | 180 | 0.010 |
Why?
|
Up-Regulation | 1 | 2002 | 862 | 0.010 |
Why?
|
Chromatin | 1 | 2001 | 554 | 0.010 |
Why?
|
Evolution, Molecular | 1 | 2001 | 672 | 0.010 |
Why?
|
Ukraine | 1 | 1997 | 13 | 0.010 |
Why?
|
Teaching Materials | 1 | 1997 | 16 | 0.010 |
Why?
|
False Negative Reactions | 1 | 1997 | 89 | 0.010 |
Why?
|
Radiometry | 1 | 1997 | 38 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 1997 | 110 | 0.010 |
Why?
|
False Positive Reactions | 1 | 1997 | 144 | 0.010 |
Why?
|
Family Practice | 1 | 1997 | 90 | 0.010 |
Why?
|
Genetic Techniques | 1 | 1997 | 106 | 0.010 |
Why?
|
Education, Medical, Continuing | 1 | 1997 | 138 | 0.010 |
Why?
|
Nocodazole | 1 | 1995 | 14 | 0.010 |
Why?
|
Attitude to Health | 1 | 1997 | 261 | 0.010 |
Why?
|
Genes, Viral | 1 | 1995 | 184 | 0.010 |
Why?
|
Papillomaviridae | 1 | 1995 | 137 | 0.010 |
Why?
|
Research Design | 1 | 1997 | 687 | 0.010 |
Why?
|
Flow Cytometry | 1 | 1995 | 802 | 0.010 |
Why?
|
Pheochromocytoma | 1 | 1990 | 34 | 0.010 |
Why?
|
Adrenal Gland Neoplasms | 1 | 1990 | 66 | 0.010 |
Why?
|
Adenocarcinoma | 1 | 1995 | 998 | 0.000 |
Why?
|
DNA, Circular | 1 | 1986 | 18 | 0.000 |
Why?
|
Lung Neoplasms | 1 | 1995 | 1604 | 0.000 |
Why?
|
Mollusca | 1 | 1982 | 9 | 0.000 |
Why?
|
Electron Spin Resonance Spectroscopy | 1 | 1982 | 22 | 0.000 |
Why?
|
Arthropods | 1 | 1982 | 26 | 0.000 |
Why?
|
Species Specificity | 1 | 1982 | 548 | 0.000 |
Why?
|
Oxygen | 1 | 1982 | 554 | 0.000 |
Why?
|